- Stocks
- Healthcare
- NYSE: ABBV

Price (delayed)

$193.58

Market cap

$341.93B

P/E Ratio

64.53

Dividend/share

$6.13

EPS

$3

Enterprise value

$399.43B

AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories. On October 19, 2011, Abbott Laboratories announced its plan to separate

The debt rose by 16% year-on-year but it has declined by 4.5% since the previous quarter

ABBV's P/E is 108% above its 5-year quarterly average of 31.0 and 24% above its last 4 quarters average of 52.2

AbbVie's equity has decreased by 47% YoY and by 15% from the previous quarter

What are the main financial stats of ABBV

Market
Valuations
Earnings

Shares outstanding

1.77B

Market cap

$341.93B

Enterprise value

$399.43B

Price to earnings (P/E)

64.53

Price to book (P/B)

50.43

Price to sales (P/S)

6.22

EV/EBIT

45.44

EV/EBITDA

23.08

EV/Sales

7.26

Revenue

$55B

EBIT

$8.79B

EBITDA

$17.31B

Free cash flow

$17.78B

Per share
Balance sheet
Liquidity

EPS

$3

Free cash flow per share

$10.06

Book value per share

$3.84

Revenue per share

$31.11

TBVPS

$27.32

Total assets

$141.94B

Total liabilities

$135.12B

Debt

$70.63B

Equity

$6.78B

Working capital

-$8.1B

Debt to equity

10.42

Current ratio

0.81

Quick ratio

0.59

Net debt/EBITDA

3.32

Margins
Efficiency
Dividend

EBITDA margin

31.5%

Gross margin

62.8%

Net margin

9.7%

Operating margin

22.3%

Return on assets

3.8%

Return on equity

57.3%

Return on invested capital

14.3%

Return on capital employed

8.8%

Return on sales

16%

Dividend yield

3.17%

DPS

$6.13

Payout ratio

204.3%

How has the AbbVie stock price performed over time

Intraday

0.07%

1 week

-0.52%

1 month

-0.17%

1 year

25.75%

YTD

24.91%

QTD

12.86%

How have AbbVie's revenue and profit performed over time

Revenue

$55B

Gross profit

$34.52B

Operating income

$12.27B

Net income

$5.34B

Gross margin

62.8%

Net margin

9.7%

The company's net income fell by 39% YoY and by 11% QoQ

The net margin has declined by 37% year-on-year and by 12% since the previous quarter

The operating income has contracted by 29% YoY and by 4% from the previous quarter

The operating margin has declined by 28% year-on-year and by 5% since the previous quarter

What is AbbVie's growth rate over time

What is AbbVie stock price valuation

P/E

64.53

P/B

50.43

P/S

6.22

EV/EBIT

45.44

EV/EBITDA

23.08

EV/Sales

7.26

ABBV's P/E is 108% above its 5-year quarterly average of 31.0 and 24% above its last 4 quarters average of 52.2

The EPS has contracted by 39% YoY and by 11% from the previous quarter

ABBV's price to book (P/B) is 156% higher than its 5-year quarterly average of 19.7 and 51% higher than its last 4 quarters average of 33.3

AbbVie's equity has decreased by 47% YoY and by 15% from the previous quarter

How efficient is AbbVie business performance

AbbVie's return on assets has decreased by 40% YoY and by 12% QoQ

The ROS has contracted by 27% YoY and by 5% from the previous quarter

AbbVie's ROIC has decreased by 26% YoY and by 6% from the previous quarter

The ROE has grown by 3.6% from the previous quarter but it has contracted by 2.1% YoY

What is ABBV's dividend history

DPS

$6.13

Dividend yield

3.17%

Payout ratio

204.3%

Recent dividends

Special dividends are included in TTM DPS and yield

How did AbbVie financials performed over time

AbbVie's total assets is 5% higher than its total liabilities

The quick ratio has contracted by 18% from the previous quarter and by 6% YoY

ABBV's current ratio is down by 14% since the previous quarter and by 9% year-on-year

The company's debt to equity has surged by 120% YoY and by 13% QoQ

AbbVie's equity has decreased by 47% YoY and by 15% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.